RE:RE:RE:Question for the Pharma SavvyI didn't know HCA does grants. Wouldn't that be a conflict of interest? Incremental milestone based acquisition from a larger entity ($3 - $7 - $10) would be par for the course, if and when they do get BTD. Like everyone else, I'm just hoping they get BTD first. After 3 NRs, we all know what's likely to happen in the next few weeks. They are probably out of money about now.
Rumpl3StiltSkin wrote: N0taP00p wrote: For many (not all) companies at this stage of development and with so much promise, one would think a $300M to $500 M market cap is very reasonable. At least a dollar+ per share. The IP is there, the initial results seem to beat or equal the best out there, safety looks good, and all with just one or two treatments. So what gives? I think it's a combination of the exchange they're on, execution history, unknown names on BOD and exec team wrt go-to-market and scaling experience, and PDT still being on the fringes of oncology for the most part. The last two to three NRs were impressive and reinforced our faith in the science and the drug itself. You just have to hope the FDA will see the potential. Or least another pharma looking for a 10 year diversified pipeline based on Ruvidar. Why not buy a third of the company for 2 bucks and the rest of the acquisition based on meeting BTD and other goals? $200M seems like an informed bet (phase 2, close to BTD) for a hungry pharma.
Poop,
I'd like to see Health Canada give them a grant in that $$ range. Then Let's see what kind of a real deal Dr. LBiati can get from a Pharma??